Tourmaline Bio, Inc. (TRML) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TRML currently has 25.8M outstanding shares. with moderate dilution risk from 10.1M authorized shares representing 39.4% potential dilution. The company has minimally diluted shareholders by 1.77% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Aug 13, 2025 |
10-Q filing | 25.8M shares outstanding |
26M | 10M |
| May 02, 2025 |
10-Q filing | 25.7M shares outstanding |
26M | 10M |
| Mar 13, 2025 |
10-K filing | 25.3M shares outstanding |
25M | 10M |
| Nov 07, 2024 |
S-3 filing: This S-3 filing describes an at-the-market offering of common stock through a placement agent. The company or agent may suspend sales, and sales will not occur if the company has material non-public information. |
26M | 10M |
| Nov 07, 2024 |
10-Q filing | 25.8M shares outstanding |
26M | 10M |
| Aug 08, 2024 |
10-Q filing | 25.7M shares outstanding |
26M | 10M |
| May 13, 2024 |
10-Q filing | 24.1M shares outstanding |
24M | 10M |
| Mar 19, 2024 |
10-K filing | 25.6M shares outstanding |
26M | 10M |
| Nov 14, 2023 |
10-Q filing | 20.3M shares outstanding |
20M | 10M |
| Aug 14, 2023 |
10-Q filing | 42.2M shares outstanding |
42M | 10M |
| May 15, 2023 |
10-Q filing | 41.8M shares outstanding |
42M | 10M |
| Mar 31, 2023 |
10-K filing | 41.2M shares outstanding |
41M | 10M |
| Nov 10, 2022 |
10-Q filing | 41.4M shares outstanding |
41M | 10M |
| Aug 15, 2022 |
S-3 filing: The company is filing an S-3 to offer up to $250,000,000 in common stock, preferred stock, debt securities, warrants and/or units, and is also offering up to $75,000,000 in common stock through an at-the-market offering with SVB Securities as the sales agent. |
41M | 10M |
| Aug 15, 2022 |
10-Q filing | 41.1M shares outstanding |
41M | 10M |
| May 12, 2022 |
10-Q filing | 41.5M shares outstanding |
41M | 10M |
| Mar 17, 2022 |
10-K filing | 41.5M shares outstanding |
41M | 10M |
| Nov 12, 2021 |
10-Q filing | 41.4M shares outstanding |
41M | 10M |
| Aug 12, 2021 |
10-Q filing | 41.3M shares outstanding |
41M | 10M |
| Jun 14, 2021 |
10-Q filing | 41.3M shares outstanding |
41M | 10M |
| May 03, 2021 |
S-1/A filing: This S-1/A filing relates to an offering of common stock and includes information about the underwriters' option to purchase additional shares, the number of common stock to be outstanding after the offering, and the use of proceeds from the offering. |
40M | 10M |
| Apr 16, 2021 |
S-1 filing: This S-1 filing details a proposed initial public offering of common stock, with the primary objectives of creating a public market for the stock, facilitating future access to public equity markets, increasing market visibility, and obtaining additional capital for ongoing clinical trials, research and development, and general corporate purposes. |
170M | 0 |